Deals in brief

Powered by

Tetraphase Pharmaceuticals to merge with AcelRx

AcelRx Pharmaceuticals has executed a definitive merger agreement to acquire Tetraphase Pharmaceuticals in a stock-based transaction.

Under the agreement, Tetraphase stockholders will receive 0.6303 of a share of AcelRx common stock for each share of Tetraphase common stock. The deal is worth around $14.4m.

Furthermore, the terms of the agreement cover one contingent value right (CVR), which will provide aggregate payments of up to $12.5m upon reaching Xerava net sales milestones beginning in 2021.

Xerava is a tetracycline developed by Tetraphase for the treatment of serious and life-threatening infections.

The deal, approved by both parties’ boards of directors, is expected to close in the second quarter of the year. Tetraphase and AcelRx also signed a separate agreement to jointly promote Xerava to treat complicated intra-abdominal infections (cIAI) and Dsuvia for acute pain in medically supervised settings.

This agreement will allow the companies to immediately benefit from the promotion of several products, along with access to respective customer networks. The combined sales team is expected to cover 70% of each party’s originally targeted hospitals.

Tetraphase Pharmaceuticals president and CEO Larry Edwards said: “This transaction is an important move forward for Tetraphase and more importantly, for Xerava and the patients who need this treatment.

“We continue to believe that Xerava is a key addition to the hospital anti-infective armamentarium, and believe that together with AcelRx we will be able to more effectively bring new treatments to patients in healthcare institutions.”

Following the closure of the deal, Tetraphase will become a privately held company.

AcelRx Pharmaceuticals CEO Vince Angotti said: “We look forward to integrating Xerava and the existing Tetraphase commercial infrastructure with our own as we strengthen our position on promoting innovative products to healthcare institutions allowing patients access to new and improved treatments.”

BioNTech acquires T cell therapy-focused Neon for $67m

BioNTech has acquired Neon Therapeutics in an all stock transaction valued at $2.18 per share or approximately $67m.

According to the terms of the deal, Neon will be merged with ENDOR Lights, a wholly owned subsidiary of BioNTech.

Applied DNA, Takis Biotech design four Covid-19 vaccine candidates

Orionis and Novartis enter drug discovery deal

Life sciences firm Orionis Biosciences has partnered with Novartis to discover and design new drugs for the treatment of a variety of diseases.

Orionis portfolio includes technologies for genome-scale drug discovery and molecular design of therapeutic modalities, intended to address the most challenging protein targets.

The four-year alliance with Novartis will leverage Orionis’ Allo-Glue technology platform to identify and design small molecule drugs, including protein degraders.

According to Orionis, the deal involves research funding, a convertible note investment, royalties and also clinical milestones.

Vir Biotechnology partners NIH and Biogen on coronavirus antibodies

BioNTech signs Covid-19 vaccine deals with Pfizer and Fosun

Iktos and SRI to use AI for Covid-19 drug development

Artificial intelligence (AI) technology provider Iktos and research centre SRI International have partnered to discover and develop drugs to treat various viruses, including the novel coronavirus that causes Covid-19 and influenza.

Iktos will combine its generative modelling technology with SRI’s fully automated synthetic chemistry platform called SynFini to design compounds and speed-up the identification of drug candidates.

Share this article